Cytokine profiling for prediction of symptomatic radiation-induced lung injury

Hart, Justin P.; Broadwater, Gloria; Rabbani, Zahid N.; Moeller, Benjamin J.; Clough, Robert; Huang, Dale; Sempowski, Gregory D.; Dewhirst, Mark W.; Pizzo, Salvatore V.; Vujašković, Željko; Anscher, Mitchell S.

doi:10.1016/j.ijrobp.2005.05.032

Cited by 76 publications

(60 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, high levels of IL-8 have been found in the BAL fluid of patients with pneumonia and adult respiratory distress syndrome (Donnelly et al 1993, Hart et al 2005. Therefore our data support the hypothesis that inflammation induced by proinflammatory cytokines is an important trigger for the development of lung fibrosis and that the prevention of acute inflammation for example as a consequence of therapeutic irradiation may also help to prevent the development of lung fibrosis.…”

Section: Discussionsupporting

confidence: 84%

Radiation-induced matrix production of lung fibroblasts is regulated by interleukin-8

Kühlmann

Chwieralski

Reinhold

et al. 2009

International Journal of Radiation Biology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 84%

Radiation-induced matrix production of lung fibroblasts is regulated by interleukin-8

Kühlmann

Chwieralski

Reinhold

et al. 2009

International Journal of Radiation Biology

View full text Add to dashboard Cite

show abstract

“…Kong et al have shown that the loss of the M6P/IGF2 gene in patients with carcinoma of the lung is highly correlated with the development of RP after thoracic RT, and that a loss of heterozygosity are more likely to have increased plasma TGFβ, suggesting an inability to normally process this cytokine [37]. Recent analysis from our group suggests that screening pretreatment plasma samples for the presence of a panel of inflammatory and immunomodulating cytokines may permit the construction of a cytokine profile for risk assessment of lung injury [38].…”

Section: Discussionmentioning

confidence: 96%

Does transforming growth factor-β1 predict for radiation-induced pneumonitis in patients treated for lung cancer?

et al. 2006

View full text Add to dashboard Cite

The purpose of the study was to reassess the utility of transforming growth factor-beta-1 (TGF-β1) together with dosimetric and tumor parameters as a predictor for radiation pneumonitis (RP). Of the 121 patients studied, 32 (26.4%) developed grade ≥ 1 RP, and 27 (22.3%) developed grade ≥ 2 RP. For the endpoint of grade ≥ 1 RP, those with V30 > 30% and an end-RT/baseline TGF-β1 ratio ≥ 1 had a significantly higher incidence of RP than did those with V30 > 30% and an end-RT/baseline TGF-β1 ratio < 1. For most other patient groups, there were no clear associations between TGF-β1 values and rates of RP. These findings suggest that TGF-β1 is generally not predictive for RP except for the group of patients with a high V30.

show abstract

“…High plasma levels of transforming growth factor-β during the course of treatment with conventional 45 or 3D-CRT 46 were found to be associated with a higher risk of radiation pneumonitis. 47 In addition, a high level of IL-1 α, IL-6, 48 and pulmonary surfactant protein D 49 or an increase in the levels of serum mucinlike glycoprotein antigen (KL-6) 50 and cytokeratin 19 fragment (CYFRA 21-1) 51 have been associated with an increased risk of developing radiation pneumonitis.…”

Section: Pulmonary Toxicitymentioning

confidence: 99%

Management of Normal Tissue Toxicity Associated With Chemoradiation (Primary Skin, Esophagus, and Lung)

Yazbeck¹,

Villaruz²,

Haley³

et al. 2013

The Cancer Journal

View full text Add to dashboard Cite

Nearly one quarter of patients with lung cancer present with locally advanced disease where concurrent chemoradiotherapy is the current standard of care for patients with good performance status. Cisplatin-based concurrent chemoradiotherapy consistently showed an improvement in survival compared with sequential chemoradiotherapy, at the expense of an increase in the toxicity profile. Over the past decades, several encouraging biomarkers such as transforming growth factor-beta and radioprotective agents such as amifostine were studied but without reaching approval for patient care. We reviewed the prevalence and risk factors for different adverse effects associated with the combined chemoradiotherapy modality, especially dermatitis, mucositis, esophagitis, and pneumonitis. These adverse effects can further be divided into acute, subacute, and chronic. Dermatitis is usually rare and responds well to topical steroids and usual skin care. Acute esophagitis occurs in 30% of patients and is treated with proton pump inhibitors, promotility agents, local anesthetic, and dietary changes. Radiation pneumonitis is a subacute complication seen in 15% of patients and is usually managed with steroids. Chronic adverse effects such as radiation fibrosis and esophageal stricture occur approximately 6 months after completion of radiation therapy and are usually permanent. In this review, complications of chemoradiotherapy for patients with locally advanced lung cancer are delineated, and approaches to their management are described. Given that treatment interruption is associated with a worse outcome, patients are aggressively treated with a curative intent. Therefore, planning for treatment adverse effects improves patient tolerance, compliance, and outcome.

show abstract

Cytokine profiling for prediction of symptomatic radiation-induced lung injury

Cited by 76 publications

References 39 publications

Radiation-induced matrix production of lung fibroblasts is regulated by interleukin-8

Radiation-induced matrix production of lung fibroblasts is regulated by interleukin-8

Does transforming growth factor-β1 predict for radiation-induced pneumonitis in patients treated for lung cancer?

Management of Normal Tissue Toxicity Associated With Chemoradiation (Primary Skin, Esophagus, and Lung)

Contact Info

Product

Resources

About